Before Seeking Cancer Treatment Abroad: Is Your Diagnosis Really Accurate? The Vital Importance of Pathology Report Review

1. Why Cancer Diagnosis Accuracy Is the Most Critical First Step Before Any Treatment Decision

Receiving a cancer diagnosis is one of the most emotionally overwhelming experiences a person can face. In the immediate aftermath, the instinct is to act — to begin treatment as quickly as possible, to seek the best specialist, to explore every option including seeking medical care abroad. This urgency is entirely understandable. But it can also lead to one of the most consequential mistakes a cancer patient can make: proceeding with treatment based on a diagnosis that has not been rigorously verified.

The foundation of every cancer treatment decision — whether surgery, chemotherapy, radiation, immunotherapy, or targeted therapy — is the pathology report. This document, produced by a pathologist who examines tissue samples taken from your body, determines what type of cancer you have, how aggressive it is, and what stage it has reached. Every treatment protocol that follows is built upon this foundation. If the foundation contains errors, the entire treatment plan may be built upon incorrect assumptions.

For patients who are considering seeking medical treatment abroad — including those exploring world-class oncology care at leading institutions in China — the accuracy of your pathology report takes on even greater significance. International specialists cannot provide optimal treatment guidance without a reliable, verified diagnosis. A misdiagnosis does not simply lead to ineffective treatment; it can lead to receiving toxic therapies for a condition you do not have, failing to receive appropriate treatment for the condition you do have, or making irreversible surgical decisions based on incorrect staging information.

MedBridge was founded precisely to address this gap in the medical decision-making process. As a cross-border healthcare service platform connecting patients in North America and Europe with world-class medical expertise — including China's internationally trained oncology and pathology specialists — we have observed firsthand how pathology report verification changes treatment trajectories. In many cases, it has been the single intervention that transformed a patient's outcome from catastrophic to genuinely hopeful.

This guide is designed to provide you with a comprehensive, honest, and practically useful understanding of why pathology report accuracy matters, how diagnostic errors occur, what your pathology report should contain, when and how to seek a second opinion, and how China's leading oncology centers — accessible through MedBridge — can provide world-class diagnostic verification at a fraction of Western costs. It is written for adults, without unnecessary medical jargon, in a format that respects both your intelligence and the seriousness of your situation.

1.1 The Unique Stakes of Cancer Diagnosis: Why This Is Different From Any Other Medical Condition

Cancer diagnosis is not analogous to diagnosing a broken bone or a bacterial infection. Cancer exists in an almost bewildering variety of types, subtypes, grades, and molecular profiles — each with fundamentally different treatment implications. Two tumors that look virtually identical under a standard microscope may behave completely differently biologically, respond to entirely different treatments, and carry vastly different prognoses. The revolution in molecular pathology, genetic sequencing, and biomarker testing over the past two decades has transformed oncology, but it has also dramatically increased the complexity of accurate diagnosis.

Consider a patient diagnosed with what appears to be a standard breast cancer. Without comprehensive molecular profiling — including hormone receptor status (ER, PR), HER2 status, Ki-67 proliferation index, and potentially next-generation gene sequencing — two pathologists looking at the same tissue sample could reach diagnoses that lead to completely different treatment pathways. One might recommend aggressive chemotherapy; another might identify a hormone-receptor-positive, low-grade tumor appropriately managed with targeted hormonal therapy and without chemotherapy at all.

This complexity means that getting your pathology report reviewed by a qualified expert specialist before committing to any treatment — and certainly before traveling abroad for treatment — is not a luxury or an act of distrust toward your original physician. It is a fundamental act of informed medical decision-making that the world's leading cancer centers actively encourage.

1.2 The Medical Tourism Context: Special Risks When Crossing Borders for Cancer Care

For patients exploring cancer treatment abroad — whether motivated by cost considerations, access to treatments not available domestically, shorter waiting times, or the reputation of specific international centers — the pathology verification question becomes even more pressing. When you travel internationally for cancer treatment, you are placing yourself in the care of physicians who are working from the documentation you bring with them. If that documentation contains errors, inconsistencies, or lacks the molecular detail that modern oncology requires, the entire treatment plan built upon it is compromised from the outset.

China's leading cancer centers — including the hospitals accessible through MedBridge — are acutely aware of this challenge. They operate dedicated international patient pathology review programs specifically designed to verify diagnoses brought from overseas before treatment begins. These programs combine advanced molecular pathology capabilities, subspecialty expertise in specific cancer types, and rigorous review processes that frequently identify clinically significant discrepancies in diagnoses originating from Western institutions. This is not a criticism of Western pathology — it is a reflection of the complexity of cancer diagnosis and the genuine value of expert subspecialty review in any healthcare system.

2. What Is a Pathology Report and Why Does It Drive Every Cancer Treatment Decision?

A pathology report is a formal medical document produced by a licensed pathologist — a physician who specializes in the diagnosis of disease through the laboratory examination of tissue, cells, and body fluids. When a suspicious lump, growth, or abnormality is identified, a sample of tissue is obtained through biopsy or surgical resection, processed in a laboratory, and examined microscopically and through various laboratory tests. The pathology report is the written summary of these findings.

Understanding what your pathology report contains — and what it should contain — is the first step toward being able to evaluate its completeness and accuracy. Many patients receive their pathology report but never review it in detail, either because they find the terminology intimidating or because they assume their doctor has reviewed it adequately. Both of these responses, while understandable, leave you vulnerable to proceeding on the basis of an incomplete or erroneous evaluation.

2.1 The Essential Components Every Complete Cancer Pathology Report Must Include

• Patient and specimen identification: Your name, date of birth, medical record number, the date of specimen collection, and the specific anatomical site from which the tissue was taken. Any discrepancy in this basic identifying information is an immediate red flag.
• Clinical history and indication: A brief summary of the clinical context — symptoms, imaging findings, prior relevant medical history — that motivated the biopsy. The pathologist's interpretation should be contextually informed.
• Gross description: A physical description of the tissue sample as received — its dimensions, color, consistency, and any macroscopically visible features. This establishes a baseline record of what was examined.
• Microscopic description: A detailed account of what the pathologist observed when examining the tissue under the microscope. This includes cell architecture, nuclear features, mitotic activity (how rapidly cells are dividing), and relationship to surrounding tissue.
• Special stains and immunohistochemistry (IHC) results: For most cancer diagnoses, standard microscopy is supplemented by special stains and antibody-based tests that identify specific proteins expressed by cancer cells. These tests are essential for accurate cancer type classification.
• Molecular and genetic testing results: For many cancers, molecular profiling — including mutation analysis, gene expression profiling, and next-generation sequencing — is now considered standard of care. The absence of appropriate molecular testing in a pathology report is a significant concern.
• Diagnosis (final pathological diagnosis): A clear statement of the pathologist's conclusion — the specific cancer type, histological subtype, grade, and any other relevant diagnostic qualifiers.
• Staging information: Where applicable, the pathological staging (pTNM) describing tumor size and invasion depth (T), lymph node involvement (N), and presence of distant metastasis (M).
• Margins and resection status: For surgical specimens, whether the surgical margins are clear of cancer cells (negative margins) or contain cancer (positive margins) — a critical factor for further treatment planning.
• Pathologist's name and credentials: The identifying information of the pathologist who prepared the report, including their institutional affiliation.

2.2 Biomarker Testing: The Molecular Foundation of Modern Targeted Cancer Treatment

One of the most consequential advances in oncology over the past two decades has been the identification of specific molecular markers — proteins, gene mutations, gene expression patterns — that both characterize specific cancer subtypes and predict response to targeted therapies. Without comprehensive biomarker testing, it is impossible to know whether a patient is eligible for some of the most effective modern cancer treatments available.

For example, in non-small cell lung cancer (NSCLC), testing for mutations in EGFR, ALK, ROS1, BRAF, MET, RET, and KRAS genes — as well as PD-L1 expression levels — is now considered essential before treatment planning. Patients with EGFR-mutant NSCLC who receive targeted EGFR inhibitors such as osimertinib have dramatically better outcomes than those treated with standard chemotherapy. But this treatment is only appropriate and effective for patients who actually have the EGFR mutation. Without the testing, neither the physician nor the patient can know this.

2.3 The Difference Between a General Pathologist and a Cancer Subspecialist Pathologist

Not all pathologists have equivalent expertise in cancer diagnosis, and this distinction matters enormously. Most hospitals — including many community hospitals where biopsies are initially performed — employ general pathologists who are competent across a broad range of diagnostic tasks. However, cancer pathology has become so specialized that the most accurate diagnoses for complex or uncommon cancer types require evaluation by a subspecialty pathologist who focuses exclusively on that specific cancer category.

A pathologist who specializes in hematopathology — the pathology of blood cancers — will have a depth of expertise in lymphomas, leukemias, and myeloma that a general pathologist simply cannot match. Similarly, a subspecialty pathologist focused on soft tissue sarcomas will identify subtleties in the diagnosis of rare mesenchymal tumors that might be missed or misclassified by a pathologist who encounters such cases only occasionally. China's leading cancer centers employ dedicated subspecialty pathologists whose entire clinical practice is focused on specific cancer categories, making them an exceptional resource for complex or uncertain diagnoses.

2.3.1 When Should You Be Most Concerned About Pathology Accuracy?

Certain situations should heighten your awareness of the need for pathology verification. These include: diagnoses of rare or uncommon cancer types where local pathologists have limited experience; small or technically challenging biopsy samples that may not be representative; diagnoses where the recommended treatment carries significant risk of long-term toxicity or irreversible effects; situations where two treating physicians have offered different treatment recommendations based on the same pathology report (a common signal of diagnostic ambiguity); and cases where your cancer does not respond to initial treatment as expected, raising the possibility of a diagnostic error. Any of these situations warrants pathology review at a major cancer center before proceeding or modifying treatment.

3. How Diagnostic Errors Happen: Understanding the Hidden Risks in Cancer Pathology

Understanding how pathology errors occur is not about assigning blame to individual physicians — the vast majority of pathologists are highly skilled and diligent professionals working under significant time and resource constraints. It is about understanding a systemic reality: cancer pathology is extraordinarily complex, and errors — both in the form of outright misdiagnoses and in the form of incomplete characterization — occur at rates that are clinically significant.

A landmark study published in the Journal of Clinical Oncology found that when biopsy specimens from patients referred to a major cancer center were reviewed by subspecialty pathologists, clinically significant discrepancies were identified in approximately 28% of cases. In roughly 8% of these cases, the discrepancy was major enough to fundamentally change the treatment plan. For a disease where treatment decisions involve chemotherapy, radiation, and surgery — each with significant risks and irreversible consequences — these statistics represent an enormous patient safety concern.

3.1 The Six Most Common Sources of Cancer Pathology Errors

3.2 Specific Cancer Types With the Highest Documented Misdiagnosis Rates

While diagnostic discrepancies can occur with any cancer type, research has consistently identified certain cancer categories as carrying higher risk of diagnostic error or clinically significant reclassification upon expert review:

3.3 The Particular Danger of False Negatives: When Cancer Is Missed Entirely

While much attention focuses on cases where a benign condition is incorrectly diagnosed as cancer (false positive — also a serious problem), the false negative scenario — where cancer is present but not identified — carries even more devastating consequences. A patient told they do not have cancer who actually does may delay treatment until the disease advances to a less treatable stage. False negative pathology reports can result from the sampling errors discussed above, from misinterpretation of subtle early-stage malignant changes, or from failure to perform appropriate special stains that would have revealed malignancy not apparent on standard microscopy. Seeking pathology review at a center with subspecialty expertise is the most reliable protection against false negative errors in complex or borderline cases.

4. The Compelling Case for Pathology Second Opinions Before Seeking Cancer Treatment Abroad

If you are considering traveling internationally for cancer treatment — to any country, including China — obtaining a verified, comprehensive pathology review before your departure is not merely advisable. It is, from a patient safety and treatment efficacy perspective, an essential prerequisite that should be treated as non-negotiable. The reasons for this are both clinical and logistical.

From a clinical standpoint, the international oncologist who will be managing your treatment needs the most accurate, complete diagnostic information available. Providing them with a pathology report that has been independently verified by a subspecialty expert — ideally including comprehensive molecular profiling — ensures that the treatment plan they develop is built on the most reliable possible foundation. Any discrepancy between the original diagnosis and the verified diagnosis is far better identified before treatment begins than after.

4.1 What a Comprehensive Pathology Second Opinion Actually Involves

A genuine pathology second opinion at a major cancer center is substantially more than a second pathologist simply looking at the same slide. A comprehensive review includes:

• Review of original slides and blocks: The original tissue slides and paraffin-embedded tissue blocks are requested from the original laboratory, allowing the reviewing pathologist to perform additional studies if needed rather than being limited to the original tests performed.
• Independent microscopic evaluation: A subspecialty pathologist reviews the tissue independently — without being anchored to the original diagnosis — to provide a genuinely independent assessment rather than a confirmation bias-prone "review" of an established diagnosis.
• Additional immunohistochemical staining: Where the reviewing pathologist identifies diagnostic uncertainty or areas where additional marker testing would be informative, additional IHC stains are performed on the original tissue.
• Molecular and genomic testing completion: Any molecular tests relevant to the suspected cancer type that were not performed in the original workup are completed, providing the comprehensive biomarker profile needed for optimal treatment selection.
• Subspecialty multidisciplinary review: At leading centers, the pathology review is contextualized within a multidisciplinary tumor board discussion that integrates pathology findings with clinical presentation, imaging, and other diagnostic information.
• Formal written report: A comprehensive written second-opinion report is produced, clearly articulating agreements, discrepancies, and clinical recommendations arising from the review.

4.2 When Is a Pathology Second Opinion Most Urgently Needed?

4.3 Addressing the Emotional Barrier: Why Patients Avoid Seeking Second Opinions

Despite the clear clinical evidence supporting pathology second opinions, many patients hesitate to seek them. The most common barriers we encounter at MedBridge are emotional rather than practical: fear of offending the original physician, anxiety that seeking a second opinion signals distrust of the healthcare system, worry that the process will delay treatment, and the exhausting reality that managing a cancer diagnosis already feels overwhelmingly complicated without adding additional appointments and evaluations.

We want to address each of these concerns directly. Seeking a pathology second opinion does not offend good physicians — it reassures them. Every experienced oncologist and pathologist understands that complex diagnoses benefit from expert review, and most will actively encourage it for difficult cases. The process does not necessarily delay treatment — a pathology review can often be completed within one to two weeks, and the risk of delayed treatment from a brief verification pause is vastly outweighed by the risk of pursuing incorrect treatment for weeks or months. And the apparent complexity of arranging a second opinion is precisely the problem that MedBridge's patient coordination services are designed to solve.

4.3.1 Telemedicine and Digital Pathology: How Remote Second Opinions Have Transformed Access

One of the most significant developments enabling the democratization of pathology second opinions has been the emergence of digital pathology and telemedicine-based second opinion services. Tissue slides can now be digitally scanned at extremely high resolution and transmitted electronically to expert pathologists anywhere in the world, who can review them remotely using specialized software with the same diagnostic accuracy as in-person slide review. This means that patients in North America and Europe can access the expertise of subspecialty pathologists at China's leading cancer centers without physically traveling — receiving a comprehensive written second-opinion report within days. MedBridge coordinates this entire process on behalf of patients, managing the technical logistics of slide digitization and secure transmission, professional medical translation where needed, and the formal reporting process.

5. How to Read, Evaluate, and Advocate Around Your Pathology Report

One of the most empowering things you can do as a cancer patient is to understand your own pathology report well enough to evaluate its completeness, ask informed questions about its contents, and recognize when something may be missing or require clarification. You do not need a medical degree to do this. You need a systematic framework and an honest willingness to engage with information that feels uncomfortable.

We strongly encourage every patient to request a copy of their complete pathology report — not just a verbal summary from their physician. In virtually every jurisdiction in North America and Europe, you have a legal right to a copy of your medical records, including pathology reports. Request it, read it, and bring it with you to every medical appointment.

5.1 A Patient's Practical Guide to Evaluating Your Own Pathology Report

5.2 Questions Every Cancer Patient Should Ask Their Oncologist About Their Pathology Report

• Has my pathology report been reviewed by a pathologist who subspecializes in my specific type of cancer?
• Have all relevant biomarker and molecular tests been performed? Which specific tests were done and which were not?
• Is there any diagnostic uncertainty or ambiguity in the pathology findings?
• Would you recommend sending my slides to a major cancer center for subspecialty review?
• How does my pathology report influence the specific treatment you are recommending?
• Are there any clinical trial eligibility criteria I should be evaluated for based on my molecular profile?
• How confident are you in this diagnosis, and what is the evidence base for that confidence?

5.3 Understanding Pathology Terminology: A Plain-Language Reference for Patients

The language of pathology can appear impenetrable to non-specialists, but most key terms have straightforward meanings once explained. Adenocarcinoma refers to a cancer arising from glandular cells — the most common type of lung cancer, colon cancer, and a major category of breast cancer. Squamous cell carcinoma arises from squamous cells lining body surfaces — common in the lung, head and neck, and cervix. Carcinoma in situ describes cancer cells that have not yet invaded surrounding tissue — often considered a pre-invasive or very early-stage finding. Metastatic means the cancer has spread from its original location to another site in the body. Well-differentiated (Grade 1) cancer cells look relatively similar to normal cells and tend to grow slowly; poorly differentiated (Grade 3) cells look very abnormal and tend to be more aggressive. Positive margins mean cancer cells were found at the edge of the surgical specimen, suggesting incomplete removal. Ki-67 is a protein marker of cellular proliferation — a higher percentage indicates more rapidly dividing (and typically more aggressive) cancer. Understanding these terms enables patients to engage more meaningfully with both their original treating physician and with any specialists they consult for second opinions.

5.3.1 When Pathology Reports Include Language of Uncertainty: What to Do

Pathology reports sometimes include language that reflects genuine diagnostic uncertainty rather than a definitive conclusion. Phrases like "most consistent with," "cannot exclude," "atypical cells of uncertain significance," or "differential diagnosis includes" are signals that the pathologist was unable to reach a definitive conclusion. This uncertainty is honest and professionally appropriate — but it also means that treatment decisions should not be finalized until subspecialty review has resolved the diagnostic question as definitively as the available tissue allows. At MedBridge, we treat pathology reports containing uncertainty language as immediate referrals for expedited subspecialty review, recognizing that proceeding with major treatment decisions in the presence of diagnostic ambiguity is one of the highest-risk scenarios in oncology care navigation.

6. China's Oncology and Pathology Excellence: A World-Class Resource for International Patients

For patients in North America and Europe who are exploring options for both pathology verification and cancer treatment, China represents a resource that is still substantially underrecognized by Western patients. This underrecognition is, in our experience, primarily a function of information asymmetry and cultural unfamiliarity rather than any deficiency in clinical capability. The reality is that China's leading cancer hospitals and oncology research institutions have, over the past two decades, developed into genuinely world-class centers that compare favorably with the best cancer institutions anywhere in the world.

6.1 China's Oncology Infrastructure: The Evidence for World-Class Capability

• China has the world's largest volume of cancer cases annually — a clinical reality that has driven massive investment in oncology infrastructure, specialist training, and research capacity at its leading medical institutions.
• Institutions such as the Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS), Sun Yat-sen University Cancer Center, Fudan University Shanghai Cancer Center, and Peking University Cancer Hospital are internationally recognized centers of oncology excellence whose research is published in the world's leading medical journals, including the New England Journal of Medicine, The Lancet, and the Journal of Clinical Oncology.
• Many of China's senior oncologists and pathologists trained at leading Western institutions — including Harvard Medical School, MD Anderson Cancer Center, Memorial Sloan Kettering, and the Mayo Clinic — before returning to establish China-based centers of expertise.
• China's leading cancer centers have pioneered significant advances in specific cancer types that are particularly prevalent in Asian populations, including hepatocellular carcinoma, nasopharyngeal carcinoma, and certain gastric cancers — developing treatment expertise that is recognized and sought globally.
• Laboratory capabilities at China's top cancer centers include next-generation sequencing, comprehensive immunohistochemistry panels, fluorescence in situ hybridization (FISH), and liquid biopsy technologies — the full range of modern molecular diagnostics.
• China's National Accreditation Committee for Hospitals maintains rigorous accreditation standards for clinical institutions, and several of China's leading cancer hospitals hold international accreditations including JCI (Joint Commission International) certification.

6.2 The Cost Advantage: Pathology Review and Cancer Treatment in China vs. Western Countries

6.3 China's Particular Strengths: Areas Where International Expertise Is Especially Valuable

While China's leading cancer centers are capable across all major cancer types, certain areas represent particular clinical strengths that are of specific relevance to international patients seeking second opinions or treatment:

• Hepatocellular carcinoma (liver cancer): China's oncologists manage more cases of primary liver cancer than any medical system in the world, and have pioneered minimally invasive surgical techniques, transarterial chemoembolization protocols, and combination immunotherapy approaches that represent the global state of the art.
• Gastric and esophageal cancers: High-volume experience with upper gastrointestinal cancers has produced surgical and pathological expertise that significantly exceeds that available at most Western centers for these specific disease types.
• Traditional Chinese medicine (TCM) integration in oncology: China's leading cancer centers offer evidence-based integrative oncology programs that combine conventional treatments with rigorously studied TCM approaches for supportive care — reducing treatment side effects and improving quality of life during active treatment.
• Clinical trial access: China's large cancer centers are active sites for international clinical trials, including trials of novel targeted therapies and immunotherapy agents, offering international patients access to treatment options not available in their home countries.
• Robotic and minimally invasive surgical oncology: China's leading surgical oncology programs have rapidly adopted the da Vinci robotic surgical system and other minimally invasive techniques, with outcomes data comparing favorably with the best Western programs.

6.3.1 Language, Cultural Coordination, and the International Patient Experience in China

One of the most practical concerns for Western patients considering pathology review or treatment at Chinese oncology centers is navigating language barriers and cultural differences in healthcare communication. This is a legitimate consideration, and it is precisely the challenge that MedBridge's coordination infrastructure is designed to address comprehensively. MedBridge's team includes bilingual medical coordinators with clinical backgrounds who manage all communication between international patients and Chinese specialist teams, provide real-time interpretation during video consultations, translate all clinical documents including pathology reports and treatment plans into clear English, and support patients through every logistical step of the process. The clinical and cost advantages of China's leading oncology centers are fully accessible to North American and European patients through MedBridge's coordination services — without requiring patients to navigate the Chinese healthcare system independently.

7. Comparing Pathology Review Options: Local, National, and International Resources

Patients seeking pathology second opinions have multiple options available to them, each with different characteristics in terms of accessibility, cost, turnaround time, and depth of subspecialty expertise. Understanding these options allows you to make an informed decision about the most appropriate pathway for your specific situation.

7.1 A Comprehensive Comparison of Pathology Review Pathways

7.2 Why International Subspecialty Review Offers Distinct Advantages for Complex Cases

For straightforward, common cancer diagnoses at an early stage with complete biomarker testing, a second opinion from a regional or national cancer center within your home country may be entirely sufficient. However, for complex cases — including rare cancer types, unusual presentations, incomplete original workups, or diagnoses where the recommended treatment carries high risk — accessing the depth of subspecialty expertise available at China's highest-volume cancer centers through MedBridge can offer advantages that domestic options cannot match.

Volume matters enormously in complex cancer diagnosis. A pathologist at a center that diagnoses 500 cases of a particular rare sarcoma subtype per year develops a pattern recognition capability that cannot be replicated by a pathologist who encounters that tumor type five times per year. China's leading cancer centers, by virtue of serving the world's largest national patient population, routinely achieve patient volumes in specific cancer types that enable this level of experiential expertise. Combined with comprehensive molecular testing capabilities and the cost advantages documented in the table above, this makes China-based expert review through MedBridge an extremely compelling option for patients with complex diagnostic situations.

7.3 The Process of Obtaining Pathology Second Opinion: Step-by-Step Timeline

8. How MedBridge Supports Your Complete Diagnostic Verification and Cross-Border Care Journey

Navigating cancer diagnosis verification and international treatment options simultaneously represents an extraordinarily complex challenge for patients and families who are already managing the emotional, physical, and practical demands of a cancer diagnosis. MedBridge was designed specifically to reduce this complexity — to serve as a knowledgeable, trustworthy partner who understands both the medical and logistical dimensions of international cancer care and can guide patients through every step with transparency and genuine patient-centered advocacy.

We want to be clear about what MedBridge is and what we are not. We are a medical decision support and cross-border healthcare coordination platform. We are not a recruitment agency for any specific hospital, and we do not receive performance-based referral fees that would create incentives to direct patients toward specific institutions regardless of clinical fit. Every recommendation we make is clinically motivated, and every institution in our partner network has been independently vetted against rigorous criteria that prioritize clinical quality, institutional accreditation, and demonstrated track records of positive patient outcomes.

8.1 The Complete MedBridge Patient Journey: From First Contact to Long-Term Follow-Up

8.2 Our Partner Institution Vetting Standard: How MedBridge Evaluates Chinese Cancer Centers

Every oncology institution in the MedBridge partner network has been evaluated against a comprehensive, multi-domain vetting framework developed with input from oncology specialists, patient safety experts, and international healthcare accreditation professionals. The evaluation criteria include:

• Institutional accreditation: Formal verification of licensing by China's National Health Commission, and where applicable, international accreditations such as JCI certification.
• Subspecialty pathology capability: Confirmed availability of dedicated subspecialty pathologists for each major cancer category, with verified credentials and publication records.
• Molecular diagnostics infrastructure: Documented availability of comprehensive NGS testing, IHC, FISH, and liquid biopsy — with quality control certifications for the laboratory.
• Multidisciplinary tumor board practices: Verification that MDT review is standard practice for complex cases, including international patient cases.
• English-language capability: Assessment of the institution's capacity to communicate with international patients, including availability of trained medical interpreters.
• Patient outcome data: Where available, review of institution-specific outcome data for the cancer types most commonly managed by MedBridge referrals.
• International patient services infrastructure: Evaluation of dedicated international patient support services, including administrative processes, financial transparency, and patient communication standards.